Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction

No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Yuya, Horie, Takahiro, Saito, Naritatsu, Watanabe, Shin, Otani, Chiharu, Miyasaka, Yui, Kuwabara, Yasuhide, Nishino, Tomohiro, Nakao, Tetsushi, Nishiga, Masataka, Nishi, Hitoo, Nakashima, Yasuhiro, Nakazeki, Fumiko, Koyama, Satoshi, Kimura, Masahiro, Tsuji, Shuhei, Rodriguez, Randolph Ruiz, Xu, Sijia, Yamasaki, Tomohiro, Watanabe, Toshimitsu, Yamamoto, Masamichi, Yanagita, Motoko, Kimura, Takeshi, Kakizuka, Akira, Ono, Koh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834964/
https://www.ncbi.nlm.nih.gov/pubmed/31709319
http://dx.doi.org/10.1016/j.jacbts.2019.06.001
Descripción
Sumario:No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic reticulum stress, maintained adenosine triphosphate levels, and ameliorated the infarct size in a murine cardiac ischemia and reperfusion injury model. The study confirmed the cardioprotective effect of KUS121 in a porcine ischemia and reperfusion injury model. These findings confirmed that KUS121 is a promising novel therapeutic agent for myocardial infarction in conjunction with primary percutaneous coronary intervention.

Ejemplares similares